943750-65-0

Basic information

• Product Name: 5-(4-Methylpiperazin-1-yl)pyrazin-2-aMine
• Synonyms: 5-(4-Methylpiperazin-1-yl)pyrazin-2-aMine;3-(4-Methylpiperazin-1-yl)-2,5,7-triazabicyclo[4.1.0]hepta-1,3-diene;5-(4-Methyl-piperazin-1-yl)-2H-pyrazinyl-2-ylamine
• CAS NO: 943750-65-0
• Molecular Formula: C₉H₁₅N₅
• Molecular Weight: 193.2489
• Mol File: 943750-65-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 396.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.196±0.06 g/cm3(Predicted)
• PKA: 6.90±0.42(Predicted)
• CAS DataBase Reference: 5-(4-Methylpiperazin-1-yl)pyrazin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-Methylpiperazin-1-yl)pyrazin-2-aMine(943750-65-0)
• EPA Substance Registry System: 5-(4-Methylpiperazin-1-yl)pyrazin-2-aMine(943750-65-0)

Safety Data

• Hazardous Substances Data: 943750-65-0(Hazardous Substances Data)

Upstream product

• 1360056-75-2 2-(4-methylpiperazin-1-yl)-5-nitropyrazine 
• 1033330-47-0 N-acetyl-N-(4-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl)acetamide 
• 109-01-3 1-methyl-piperazine 

Downstream Products

• 1360055-34-0 6-tert-Butyl-8-fluoro-2-{2-hydroxymethyl-3-[1-methyl-5-(4-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-ylamino)-6-oxo-1,6-dihydro-pyridazin-3-yl]-phenyl}-2H-phthalazin-1-one 

Relevant articles and documents

Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors

Bromodomain-containing Protein 4 (BRD4), an ‘epigenetic reader’, regulates chromatin structure and gene expression via recognizing and binding acetylated lysine in histones. BRD4 has become a therapeutic target for cancers because it promotes the expression of the tumor genes, such as c-Myc, NF-κB, and Bcl-2. In this study, a new series of 3-methyl-1H-indazole derivatives were designed via virtual screening and structure-based optimization. All compounds were synthesized and evaluated for their inhibitory activities to BRD4-BD1 and their antiproliferative effects in cancer cell lines. Among them, several compounds (such as 9d, 9u and 9w) exhibited strong BRD4-BD1 affinities and inhibition activities, and potently suppressed MV4;11 cancer cell line proliferation. Among them, compound 9d showed excellent selectivity for BRD4 and effectively suppressed c-Myc, the downstream protein of BRD4. This study provided new lead compounds for further biological evaluation on BRD4.

4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4)

The cyclin-dependent kinases (CDKs), as complexes with their respective partners, the cyclins, are critical regulators of cell cycle progression. Because aberrant regulations of CDK4/cyclin D1 lead to uncontrolled cell proliferation, a hallmark of cancer, small-molecule inhibitors of CDK4/cyclin D1 are attractive as prospective antitumor agents. The series of 4-(phenylaminomethylene)isoquinoline-1,3(2H,4H)-dione derivatives reported here represents a novel class of potent inhibitors that selectively inhibit CDK4 over CDK2 and CDK1 activities. In the headpiece of the 4-(phenylaminomethylene) isoquinoline-1,3(2H,4H)-dione, a basic amine substitutent is required on the aniline ring for the CDK4 inhibitory activity. The inhibitory activity is further enhanced when an aryl or heteroaryl substituent is introduced at the C-6 position of the isoquinoline-1,3(2H,4H)-dione core. We present here SAR data and a CDK4 mimic model that explains the binding, potency, and selectivity of our CDK4 selective inhibitors.